METHODS OF PROTEIN PURIFICATION AND RECOVERY

Improved methods for purification and recovery of interferon-beta (IFN- beta ) and compositions comprising substantially monomeric IFN- beta are provided. In one purification method, substantially purified IFN- beta or variant thereof is precipitated and then dissolved in a guanidine hydrochloride (...

Full description

Saved in:
Bibliographic Details
Main Authors BABUKA, SUSAN, WOLFE, SID, SHIRLEY, BRET, A, ESIKOVA, IRINA, FORDHAM, DENNIS
Format Patent
LanguageEnglish
French
Published 02.05.2002
Edition7
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Improved methods for purification and recovery of interferon-beta (IFN- beta ) and compositions comprising substantially monomeric IFN- beta are provided. In one purification method, substantially purified IFN- beta or variant thereof is precipitated and then dissolved in a guanidine hydrochloride (HC1) solution. Renaturation of the protein occurs by dilution with a suitable buffer. A similar purification method absent the precipitation step is also provided. Following renaturation of the IFN- beta , residual guanidine HC1 is removed by diafiltration or dialysis with a pharmaceutically acceptable buffer to prepare pharmaceutical compositions comprising substantially monomeric IFN- beta . L'invention concerne des méthodes améliorées de récupération et de purification d'interféron-betâ (IFN- beta ) et des compositions contenant IFN- beta pratiquement monomérique. Dans une méthode de purification, on précipite et, puis, on dissout un IFN- beta pratiquement purifié ou un variant correspondant dans une solution de chlorhydrate de guanidine (HC1). La renaturation de la protéine se produit par le biais de la dilution avec un tampon approprié. Cette invention concerne aussi une méthode de purification similaire exempte de l'étape de précipitation. Suite à la renaturation de IFN- beta , on élimine le chlorhydrate de guanidine (HC1) résiduel par diafiltration ou dialyse avec un tampon acceptable pharmaceutiquement de manière à préparer des compositions pharmaceutiques renfermant IFN- beta pratiquement monomérique.
Bibliography:Application Number: WO2001US51038